IRVINE, Calif., April 7, 2016 /PRNewswire/ -- ALPHAEON Corporation today announced positive data from two Phase III clinical trials of its DWP-450 botulinum toxin type A neuromodulator at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas, NV.
DWP-450 was studied in subjects with glabellar lines, which are also known as "frown lines" between the eyebrows. In the two phase III randomized, multi-center, placebo-controlled, double blind trials (EV001 and EV002), DWP-450 successfully achieved the studies' primary efficacy endpoint. The composite endpoint required both the investigator and the study subject to independently agree that there had been at least a 2-point improvement 30 days after the treatment when compared to baseline (pre-treatment). The responder rate was 67.5% in the EV001 study and 70.4% in the EV002 study and both studies were statistically superior to their respective placebo control groups.
Chris Marmo, President of Beauty for ALPHAEON, said, "The results of our phase III clinical trials marks a significant milestone for ALPHAEON. It's a great advancement in the regulatory process and we look forward to leveraging our unique and innovative social commerce platform to offer this product to board certified specialty physicians."
Rui Avelar, MD, Chief Medical Officer of ALPHAEON, said, "Meeting the primary endpoint in these studies further contributes to the growing body of evidence for DWP-450. We look forward to the results of our ongoing clinical trials."
Additional information about the studies can be found at www.clinicaltrials.gov, clinical trial identifiers NCT02334423 and NCT02334436.
About ALPHAEON Corporation
ALPHAEON Corporation is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare. For more information, please visit www.alphaeon.com.
ALPHAEON PRESS CONTACT:
Jenna Mons, Senior Vice President of Marketing and Communications
ALPHAEON INVESTOR CONTACT:
Ashwin Agarwal, Vice President of Investor Relations and Finance
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alphaeon-announces-results-from-two-phase-iii-trials-of-dwp-450-botulinum-toxin-type-a-300247622.html
SOURCE ALPHAEON Corporation